GLP-1s and PCOS: Beyond Weight Loss

Can They Lower Insulin Resistance, Prevent Heart Disease, and Improve Reproductive Health?

Mar 09, 2026

By Dr. H. Weiss, MD OB/GYN

If you’ve been following the medical news — or social media — you’ve heard about GLP-1 receptor agonists. Ozempic, Wegovy, Mounjaro, Zepbound. These medications, originally developed for type 2 diabetes, have become household names for their dramatic weight loss effects.

But here’s what most people with PCOS don’t know: the story of GLP-1s and PCOS goes far beyond weight loss. The emerging research suggests these medications may address some of the core metabolic and reproductive dysfunctions that define PCOS — insulin resistance, cardiovascular risk, hormonal imbalance, and fertility challenges.

As a physician who has spent years treating women with PCOS, I want to walk you through what the science actually shows, what it doesn’t show, and what you should know if you’re considering these medications — or if your doctor has already suggested them.

This is not a promotion. This is education. Let’s look at the evidence.

What Are GLP-1 Receptor Agonists?

Before we talk about PCOS, let’s clarify what these medications actually are and how they work.

GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone secreted by L-cells in your intestine after you eat. Its primary jobs are to:

Stimulate insulin release from the pancreas in a glucose-dependent manner (meaning it only triggers insulin when blood sugar is elevated)
Suppress glucagon production (which normally raises blood sugar)
Slow gastric emptying (making you feel full longer)
Act on appetite centers in the brain to reduce hunger

GLP-1 receptor agonists are synthetic medications that mimic this natural hormone — but with a much longer duration of action. Where natural GLP-1 is broken down by enzymes within minutes, these medications remain active for hours to days.

Currently available GLP-1 receptor agonists include:

Liraglutide (Victoza for diabetes, Saxenda for weight management)
Semaglutide (Ozempic for diabetes, Wegovy for weight management)
Exenatide (Byetta, Bydureon)
Dulaglutide (Trulicity)
Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) — technically a dual GIP/GLP-1 agonist

For PCOS, most of the research has focused on liraglutide, semaglutide, and exenatide.

Why PCOS and GLP-1s? The Metabolic Connection

PCOS is not just a reproductive disorder. It is fundamentally a metabolic and endocrine condition in which insulin resistance plays a central role.

Here’s what we know:

70-93% of women with PCOS have insulin resistance, depending on whether they’re lean, overweight, or obese
Insulin resistance occurs even in normal-weight women with PCOS at rates around 59%
Hyperinsulinemia (high circulating insulin compensating for resistance) directly drives androgen production in the ovaries
Women with PCOS have up to 7-10 times higher risk of developing type 2 diabetes by age 40
Cardiovascular risk is significantly elevated

Given that GLP-1 receptor agonists improve insulin sensitivity, reduce body weight, lower inflammation, and have demonstrated cardiovascular protective effects in people with type 2 diabetes and obesity, the rationale for studying them in PCOS is strong.

The Evidence: What Does Research Actually Show?

Let me walk you through the key findings from clinical trials and meta-analyses published through 2025. I’ll separate this into four domains: metabolic health, reproductive health, cardiovascular risk, and safety.

1. Metabolic Improvements: Insulin, Weight, and Body Composition

Multiple randomized controlled trials and meta-analyses have now evaluated GLP-1 receptor agonists in women with PCOS. Here’s what the data shows:

Weight and Body Composition

A 2025 meta-analysis published in Scientific Reports analyzed randomized controlled trials comparing GLP-1 receptor agonists to metformin or placebo in women with PCOS. The findings:

Body Mass Index (BMI) decreased significantly: mean difference of -2.42 kg/m² (95% CI: -3.10 to -1.74, p<0.00001)
Waist circumference decreased by -5.16 cm (95% CI: -6.11 to -4.21, p<0.00001)
Body weight reductions were significantly greater with GLP-1 agonists than metformin

Importantly, one trial found that liraglutide reduced visceral adipose tissue by 18% over 26 weeks in women with PCOS — visceral fat being the metabolically dangerous fat linked to insulin resistance and cardiovascular risk.

A 2024 meta-analysis in the Progressive Cardiovascular Diseases journal found that among women with obesity and PCOS, GLP-1 agonists reduced:

Waist circumference by -5.16 cm
BMI by -2.42 points
Triglycerides by -0.20 mmol/L

These are not trivial reductions. Weight loss in PCOS is notoriously difficult, and even 5-10% body weight reduction has been shown to improve ovulation, insulin sensitivity, and androgen levels.

Insulin Sensitivity and Glucose Control

A 2019 meta-analysis in Reproductive BioMedicine Online comparing GLP-1 receptor agonists to metformin in women with PCOS found:

GLP-1 agonists significantly improved insulin sensitivity (standard mean difference -0.40, 95% CI -0.74 to -0.06, p=0.02)
They were more effective than metformin at improving insulin resistance

However, not all studies found statistically significant differences in HOMA-IR (the most common insulin resistance calculation). A 2024 meta-analysis found no significant difference in HOMA-IR between GLP-1 agonists and placebo, though fasting glucose and fasting insulin showed trends toward improvement.

What this means: The insulin sensitivity benefits are real but modest in many studies. The glucose-lowering effect is glucose-dependent, which is why improvements are more pronounced in women with prediabetes or diabetes than in those with normal glucose levels.

A Real-World Study: November 2024

In November 2024, Epic Research published observational data on 36,674 women aged 18-50 with PCOS who filled prescriptions for either a GLP-1 agonist or metformin between 2021-2024. They found:

GLP-1 agonists produced greater weight loss than metformin
GLP-1 agonists produced greater HbA1c reduction than metformin

This is real-world evidence supporting what clinical trials have shown: GLP-1s work, and they work better than metformin for metabolic outcomes in many patients.

2. Reproductive and Hormonal Improvements

This is where the data gets particularly interesting for women with PCOS who are struggling with irregular cycles, anovulation, and infertility.

Testosterone and Androgens

Multiple studies have shown GLP-1 receptor agonists reduce total testosterone levels in women with PCOS.

A 2023 meta-analysis in BMC Endocrine Disorders found that GLP-1 agonist use was associated with:

Significant reductions in total testosterone
Improvements in menstrual regularity (standardized mean difference 1.72, 95% CI 0.60 to 2.85, p<0.001)

However, not all studies have found consistent reductions in free testosterone or improvements in clinical signs of hyperandrogenism like hirsutism (excess hair growth) or acne. A 12-week trial by Zheng et al. found that exenatide did not significantly change hirsutism scores or acne severity despite weight loss.

The likely explanation: Androgen reduction occurs primarily through weight loss and improved insulin sensitivity. Direct ovarian effects of GLP-1 agonists remain under investigation. The duration of treatment (most trials are 12-26 weeks) may not be long enough to see clinical improvements in hair growth patterns, which lag hormonal changes by months.

Menstrual Regularity and Ovulation

A 2023 meta-analysis of 11 randomized controlled trials involving 840 women with PCOS found:

Menstrual regularity improved significantly with GLP-1 agonist use
Natural pregnancy rates increased (relative risk 1.72, 95% CI 1.22 to 2.43, p=0.002)

In one trial, 60% of women treated with liraglutide experienced improved menstrual cyclicity, and two women achieved spontaneous pregnancy during the study period.

A particularly striking finding came from a study by Elkind-Hirsch et al., which compared exenatide plus metformin to either drug alone. The combination therapy achieved:

86% ovulation rate (exenatide + metformin)
50% ovulation rate (exenatide alone)
29% ovulation rate (metformin alone)

Fertility Outcomes and IVF

For women undergoing fertility treatment, a pilot randomized study by Salamun et al. (2018) showed promising results. In obese women with PCOS who had poor responses to first-line fertility treatments:

Liraglutide plus metformin vs. metformin alone before IVF resulted in:
- Pregnancy rate per embryo transfer: 85.7% vs. 28.6%
- Cumulative pregnancy rate over 12 months: 69% vs. 36%

This is a small study and needs replication, but the magnitude of difference is striking.

Critical Note on Fertility Treatment: Most reproductive endocrinologists recommend discontinuing GLP-1 agonists at least 3 months before attempting conception due to limited safety data in pregnancy and the medications’ long half-lives. The improvements in metabolic health and weight loss may persist after discontinuation and improve fertility outcomes even after stopping the medication.

3. Cardiovascular and Cardiometabolic Risk Reduction

Women with PCOS face significantly elevated cardiovascular risk — higher rates of hypertension, dyslipidemia, metabolic syndrome, and potentially higher rates of cardiovascular events, especially postmenopause.

GLP-1 receptor agonists have demonstrated cardiovascular protective effects in large trials of people with type 2 diabetes and obesity. The question is whether these benefits extend to women with PCOS.

Lipid Profile Improvements

A 2024 study in the Progressive Cardiovascular Diseases journal analyzing pooled data from women with PCOS found GLP-1 agonists:

Reduced LDL cholesterol by 10.93 mg/dL
Reduced total cholesterol by 18.14 mg/dL
Reduced triglycerides by 49.1 mg/dL

A 2025 review noted that when women with PCOS were treated with liraglutide, improvements in cardiovascular risk factors included reductions in blood pressure, improved lipid profiles, and enhanced insulin sensitivity.

Blood Pressure Effects

The blood pressure data is mixed and interesting.

A meta-analysis of liraglutide studies showed a mean systolic blood pressure decrease of 2.5 mmHg within 2 weeks
However, a 2019 study in rats modeling postmenopausal PCOS found that liraglutide did not reduce blood pressure in PCOS animals, unlike in controls
Some human studies found heart rate increases with GLP-1 agonists despite metabolic benefits

The mechanism: Androgens in PCOS may activate the renin-angiotensin system (which regulates blood pressure), potentially blunting the blood pressure-lowering effects of GLP-1 agonists. This remains an area of active research.

Long-Term Cardiovascular Outcomes

Large cardiovascular outcome trials (like SUSTAIN-6 for semaglutide and LEADER for liraglutide) have shown GLP-1 agonists reduce major adverse cardiovascular events in people with type 2 diabetes. However, no long-term cardiovascular outcome trials have been conducted specifically in women with PCOS.

A 2025 narrative review in Endocrine Connections notes that GLP-1 agonists “may lower cardiovascular risks, which are elevated in PCOS” and could be “especially advantageous for postmenopausal women with PCOS,” who face heightened cardiovascular risk.

The evidence is promising but not yet definitive for PCOS populations specifically.

4. Safety, Side Effects, and Limitations

No medication is without risks. Here’s what you need to know.

Common Side Effects

The most frequently reported side effects of GLP-1 receptor agonists in women with PCOS match what’s seen in other populations:

Nausea (significantly more common than with metformin or placebo)
Vomiting
Dizziness
Diarrhea
Constipation
Fatigue

Most of these are gastrointestinal and occur primarily during the initial titration period. They often improve with dose adjustment or over time.

Serious Concerns

Pancreatitis: GLP-1 agonists carry a warning for potential pancreatitis risk. Anyone with a history of pancreatitis should not use these medications.
Thyroid concerns: In animal studies, some GLP-1 agonists increased the risk of medullary thyroid tumors. The relevance to humans is uncertain, but these medications are contraindicated in people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2.
Gallbladder disease: Rapid weight loss with GLP-1 agonists may increase the risk of gallstones.
Eating disorders and nutritional concerns: The appetite suppression can be so significant that some patients struggle to eat adequate nutrition. In people with a history of disordered eating, these medications require careful monitoring.

Pregnancy and Preconception

GLP-1 receptor agonists are FDA pregnancy category C, meaning animal studies have shown adverse effects and human data is limited.

Animal studies have shown fetal growth restriction and congenital anomalies
Human data is reassuring but limited: Large patient registries of women exposed to GLP-1 agonists in early pregnancy (for type 2 diabetes or obesity treatment) have not shown significant increases in adverse outcomes
Current recommendation: Discontinue GLP-1 agonists at least 2-3 months before attempting conception to allow for complete drug clearance

If you become pregnant while on a GLP-1 agonist, contact your physician immediately. Do not panic — the limited human data is reassuring — but the medication should be stopped.

Weight Regain After Discontinuation

This is a critical point that’s often under-discussed: weight regain after stopping GLP-1 agonists is common.

Multiple patients in clinical practice report that weight lost while on GLP-1 medications returns (sometimes with additional weight gain) after stopping. The medications do not “reset” your metabolism permanently.

This raises important questions about:

Long-term use vs. short-term treatment
The need for continued lifestyle modification during and after medication
What happens when medications are discontinued for fertility treatment

What GLP-1s DON’T Do for PCOS

In the interest of complete honesty, let’s discuss what the research has not shown:

1. They Don’t “Cure” PCOS

PCOS is a genetic-metabolic condition. GLP-1 agonists manage symptoms — sometimes very effectively — but they do not cure the underlying condition. When the medication is stopped, symptoms often return if other interventions aren’t maintained.

2. Clinical Hyperandrogenism May Not Improve Quickly

While testosterone levels may decrease, studies have shown mixed results on hirsutism, acne, and hair loss improvement. These clinical signs of hyperandrogenism often take many months to improve even with hormonal normalization.

3. Direct Ovarian Effects Are Uncertain

While GLP-1 receptors have been found in ovarian tissue, it’s unclear how much of the benefit on ovulation and menstrual regularity comes from direct ovarian effects vs. weight loss and improved insulin sensitivity.

4. They May Not Work for Everyone

Clinical trials show that 12-15% of people taking semaglutide lose less than 5% of their body weight — meaning a meaningful subset of patients don’t respond well to these medications.

5. Long-Term Safety in PCOS Is Unknown

Most PCOS studies are 12-26 weeks in duration. What happens with 5-10 years of continuous use? We don’t know. The medication class is relatively new, and women with PCOS are a population that may need lifelong metabolic management.

How GLP-1s Compare to Other PCOS Treatments

Let’s put this in context. How do GLP-1 receptor agonists stack up against existing PCOS therapies?

GLP-1 Agonists vs. Metformin

Metformin has been the gold-standard pharmacological treatment for insulin resistance in PCOS for decades.

What the head-to-head studies show:

GLP-1 agonists produce greater weight loss than metformin
GLP-1 agonists are more effective at improving insulin sensitivity in most (but not all) studies
GLP-1 agonists produce greater reductions in BMI and waist circumference
Combination therapy (GLP-1 agonist + metformin) appears more effective than either alone for ovulation and fertility

Trade-offs:

Metformin is oral, inexpensive, generic, and has decades of safety data
GLP-1 agonists require injection (though weekly formulations exist), are expensive, and have more GI side effects
Metformin is generally considered safe in pregnancy (though typically discontinued); GLP-1s are not

GLP-1 Agonists vs. Lifestyle Modification

Lifestyle modification (diet, exercise, stress management) remains first-line therapy for PCOS per international guidelines.

GLP-1 agonists have been studied specifically in women with PCOS who failed to achieve adequate weight loss with lifestyle modification alone. In this context, they are an effective add-on therapy, not a replacement.

Weight loss achieved through sustained lifestyle change does not carry the risk of weight regain seen when medications are stopped.

GLP-1 Agonists vs. Inositol

Inositol supplements (specifically myo-inositol + D-chiro-inositol at a 40:1 ratio) have strong evidence for improving insulin sensitivity, ovulation, and fertility in PCOS.

Inositol is:

Oral, not injected
Well-tolerated with minimal side effects
Significantly less expensive
Safe in pregnancy

However, inositol does not produce the dramatic weight loss seen with GLP-1 agonists.

The Role of Oral Contraceptives

For women not seeking pregnancy, combined oral contraceptives remain a highly effective treatment for:

Regulating menstrual cycles
Reducing androgen levels
Treating hirsutism and acne
Protecting the endometrium from hyperplasia

GLP-1 agonists do not replace OCPs for these indications. They address different aspects of PCOS.

Who Might Benefit Most from GLP-1 Therapy in PCOS?

Based on the current evidence, GLP-1 receptor agonists may be most beneficial for:

1. Women with PCOS + Significant Insulin Resistance

Elevated fasting insulin
HOMA-IR > 2.5-3.0
Prediabetes or type 2 diabetes
Metabolic syndrome

2. Women with PCOS + Obesity Who Have Not Responded to Lifestyle Modification

BMI >30 (or >27 with comorbidities)
Previous unsuccessful attempts at sustained weight loss
Visceral adiposity (increased waist circumference)

3. Women with PCOS + Anovulatory Infertility

Especially if planning fertility treatment in the future
Use as preconception therapy (discontinued 2-3 months before attempting pregnancy)
May improve ovulation rates and IVF outcomes

4. Women with PCOS + Elevated Cardiovascular Risk

Dyslipidemia (high triglycerides, low HDL)
Hypertension
Fatty liver disease
Strong family history of cardiovascular disease

Practical Considerations: What to Discuss with Your Doctor

If you’re considering GLP-1 therapy for PCOS, here are the questions you should ask:

Before Starting:

Have I had comprehensive metabolic testing?
- Fasting insulin and glucose
- HOMA-IR calculation
- HbA1c
- Lipid panel
- Liver function tests
- Thyroid function
Do I have contraindications?
- Personal or family history of medullary thyroid cancer
- History of pancreatitis
- History of eating disorders
- Pregnancy or planning pregnancy in the next 6 months
- Severe gastroparesis
What is the goal of treatment?
- Weight loss?
- Improved insulin sensitivity?
- Menstrual regularity?
- Preconception preparation?
What is the plan for duration?
- Short-term (3-6 months) vs. longer-term use?
- What happens when we stop the medication?
- What other interventions will support long-term success?
What about cost and access?
- Insurance coverage for GLP-1 agonists varies widely
- Out-of-pocket costs can be $900-$1,500/month without insurance

Dr. Herman Weiss

Discussion about this post

Ready for more?